000180113 001__ 180113
000180113 005__ 20240229145606.0
000180113 0247_ $$2doi$$a10.1371/journal.pone.0268922
000180113 0247_ $$2pmid$$apmid:35622857
000180113 0247_ $$2altmetric$$aaltmetric:128954071
000180113 037__ $$aDKFZ-2022-01106
000180113 041__ $$aEnglish
000180113 082__ $$a610
000180113 1001_ $$aKoskinen, Anni$$b0
000180113 245__ $$aIncidence and survival in laryngeal and lung cancers in Finland and Sweden through a half century.
000180113 260__ $$aSan Francisco, California, US$$bPLOS$$c2022
000180113 3367_ $$2DRIVER$$aarticle
000180113 3367_ $$2DataCite$$aOutput Types/Journal article
000180113 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1653989674_21815
000180113 3367_ $$2BibTeX$$aARTICLE
000180113 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180113 3367_ $$00$$2EndNote$$aJournal Article
000180113 520__ $$aGlobal survival studies have shown favorable development in most cancers but few studies have considered laryngeal cancer, particularly over extended periods or in populations for which medical care is essentially free of charge. We analyzed laryngeal and lung cancer incidence and survival in Finland (FI) and Sweden (SE) over a 50-year period (1970-2019) using data and statistical tools from the Nordcan database. Laryngeal cancer reached an incidence maximum in FI men in 1965, which in SE men occurred over 10 years later and peaking at 42% of the FI maximum. The FI incidence halved in 20 years while halving of the SE rate took almost twice as long. At maximum the male rate exceeded the female rate 20 times in FI and 10 times in SE. Incidence rates for lung cancer were approximately 10 times higher than those for laryngeal cancer, and they peaked 5 to 10 years after laryngeal cancer in both countries. The female lung cancer rates increased through the follow-up time but laryngeal cancer rates were relatively stable. Relative 1-year survival data for laryngeal cancer remained at around 85% through 50 years, and 5-year survival lagged constantly around 65%. For lung cancer 1-year survival improved and reached about 50% by 2019. Even 5-year survival improved reaching 20 to 30%, except for FI men. Incidence rates for laryngeal and lung cancers have drastically decreased in FI and SE men parallel to reduced smoking prevalence. In females, rates have clearly increased in lung but not in FI laryngeal cancer. This finding warrants further investigations into possible contributing factors, other than smoking. Survival in laryngeal cancer has not improved compared to the positive development in lung cancer. Historical smoking prevalence was unrelated of survival trends. As long-term survival in these cancers remains discouraging, the most efficient way to fight them is to target the main cause and promote non-smoking.
000180113 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000180113 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180113 7001_ $$aHemminki, Otto$$b1
000180113 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b2$$udkfz
000180113 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b3$$udkfz
000180113 773__ $$0PERI:(DE-600)2267670-3$$a10.1371/journal.pone.0268922$$gVol. 17, no. 5, p. e0268922 -$$n5$$pe0268922 -$$tPLOS ONE$$v17$$x1932-6203$$y2022
000180113 909CO $$ooai:inrepo02.dkfz.de:180113$$pVDB
000180113 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000180113 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000180113 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000180113 9141_ $$y2022
000180113 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-02-04
000180113 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000180113 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000180113 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000180113 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-04
000180113 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-04
000180113 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPLOS ONE : 2021$$d2022-11-16
000180113 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-16
000180113 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-16
000180113 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-04-12T10:14:32Z
000180113 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-04-12T10:14:32Z
000180113 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-04-12T10:14:32Z
000180113 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-16
000180113 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-16
000180113 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-16
000180113 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-16
000180113 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-16
000180113 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2022-11-16
000180113 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-16
000180113 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000180113 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000180113 980__ $$ajournal
000180113 980__ $$aVDB
000180113 980__ $$aI:(DE-He78)B062-20160331
000180113 980__ $$aI:(DE-He78)HD01-20160331
000180113 980__ $$aUNRESTRICTED